000291634 001__ 291634
000291634 005__ 20250825134235.0
000291634 0247_ $$2doi$$a10.1016/j.pharmthera.2024.108670
000291634 0247_ $$2pmid$$apmid:38823489
000291634 0247_ $$2ISSN$$a0163-7258
000291634 0247_ $$2ISSN$$a1879-016X
000291634 0247_ $$2altmetric$$aaltmetric:165245374
000291634 037__ $$aDKFZ-2024-01458
000291634 041__ $$aEnglish
000291634 082__ $$a610
000291634 1001_ $$0P:(DE-HGF)0$$aLogotheti, Stella$$b0$$eFirst author
000291634 245__ $$aIntercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy.
000291634 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2024
000291634 3367_ $$2DRIVER$$aarticle
000291634 3367_ $$2DataCite$$aOutput Types/Journal article
000291634 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721043240_17124$$xReview Article
000291634 3367_ $$2BibTeX$$aARTICLE
000291634 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291634 3367_ $$00$$2EndNote$$aJournal Article
000291634 500__ $$a#EA:E041# / Biomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
000291634 520__ $$aAdvances in cancer therapeutics have improved patient survival rates. However, cancer survivors may suffer from adverse events either at the time of therapy or later in life. Cardiovascular diseases (CVD) represent a clinically important, but mechanistically understudied complication, which interfere with the continuation of best-possible care, induce life-threatening risks, and/or lead to long-term morbidity. These concerns are exacerbated by the fact that targeted therapies and immunotherapies are frequently combined with radiotherapy, which induces durable inflammatory and immunogenic responses, thereby providing a fertile ground for the development of CVDs. Stressed and dying irradiated cells produce 'danger' signals including, but not limited to, major histocompatibility complexes, cell-adhesion molecules, proinflammatory cytokines, and damage-associated molecular patterns. These factors activate intercellular signaling pathways which have potentially detrimental effects on the heart tissue homeostasis. Herein, we present the clinical crosstalk between cancer and heart diseases, describe how it is potentiated by cancer therapies, and highlight the multifactorial nature of the underlying mechanisms. We particularly focus on radiotherapy, as a case known to often induce cardiovascular complications even decades after treatment. We provide evidence that the secretome of irradiated tumors entails factors that exert systemic, remote effects on the cardiac tissue, potentially predisposing it to CVDs. We suggest how diverse disciplines can utilize pertinent state-of-the-art methods in feasible experimental workflows, to shed light on the molecular mechanisms of radiotherapy-related cardiotoxicity at the organismal level and untangle the desirable immunogenic properties of cancer therapies from their detrimental effects on heart tissue. Results of such highly collaborative efforts hold promise to be translated to next-generation regimens that maximize tumor control, minimize cardiovascular complications, and support quality of life in cancer survivors.
000291634 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000291634 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291634 650_7 $$2Other$$aBig data
000291634 650_7 $$2Other$$aCancer
000291634 650_7 $$2Other$$aCancer therapy
000291634 650_7 $$2Other$$aCardiooncology
000291634 650_7 $$2Other$$aCardiovascular diseases
000291634 650_7 $$2Other$$aIntercellular pathways
000291634 650_7 $$2Other$$aMultidisciplinary research
000291634 650_7 $$2Other$$aMultimodal omics
000291634 650_7 $$2Other$$aRadiotherapy
000291634 650_7 $$2Other$$aRadiotherapy-induced CVDs
000291634 650_7 $$2Other$$aSystems medicine
000291634 7001_ $$aPavlopoulou, Athanasia$$b1
000291634 7001_ $$aRudsari, Hamid Khoshfekr$$b2
000291634 7001_ $$aGalow, Anne-Marie$$b3
000291634 7001_ $$aKafalı, Yağmur$$b4
000291634 7001_ $$aKyrodimos, Efthymios$$b5
000291634 7001_ $$aGiotakis, Aris I$$b6
000291634 7001_ $$aMarquardt, Stephan$$b7
000291634 7001_ $$aVelalopoulou, Anastasia$$b8
000291634 7001_ $$aVerginadis, Ioannis I$$b9
000291634 7001_ $$aKoumenis, Constantinos$$b10
000291634 7001_ $$aStiewe, Thorsten$$b11
000291634 7001_ $$aZoidakis, Jerome$$b12
000291634 7001_ $$aBalasingham, Ilangko$$b13
000291634 7001_ $$aDavid, Robert$$b14
000291634 7001_ $$aGeorgakilas, Alexandros G$$b15
000291634 773__ $$0PERI:(DE-600)1500663-3$$a10.1016/j.pharmthera.2024.108670$$gVol. 260, p. 108670 -$$p108670$$tPharmacology & therapeutics$$v260$$x0163-7258$$y2024
000291634 8564_ $$uhttps://inrepo02.dkfz.de/record/291634/files/1-s2.0-S0163725824000901-main.pdf
000291634 8564_ $$uhttps://inrepo02.dkfz.de/record/291634/files/1-s2.0-S0163725824000901-main.pdf?subformat=pdfa$$xpdfa
000291634 909CO $$ooai:inrepo02.dkfz.de:291634$$pVDB
000291634 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000291634 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000291634 9141_ $$y2024
000291634 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000291634 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACOL THERAPEUT : 2022$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000291634 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bPHARMACOL THERAPEUT : 2022$$d2023-10-21
000291634 9201_ $$0I:(DE-He78)E041-20160331$$kE041$$lMed. Physik in der Radioonkologie$$x0
000291634 9200_ $$0I:(DE-He78)E041-20160331$$kE041$$lMed. Physik in der Radioonkologie$$x0
000291634 980__ $$ajournal
000291634 980__ $$aVDB
000291634 980__ $$aI:(DE-He78)E041-20160331
000291634 980__ $$aUNRESTRICTED